Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.

依托泊苷或者烷化剂的治疗应该每年接受全血细胞计数，监测髓发或继发性白血病的发生迹象。

We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.

40%,其中因临床标本采集和运输当造成的标本质量问题占72。